Boutignon & Partners (from mice to men)

Scientific Advisor in the field of early pharmaceutical Research & Development, I help my partners navigate and avoid common pitfalls from the moment a lead is identified until it becomes a product ready for patient administration.

BACKGROUND

Inserm
Université de Lille

PhD student in protein biochemistry on **structure/activity relationship of a complex glycolipoprotein**, the variable surface antigen (VSG) of trypanosomes.

UNIVERSITY OF OXFORD

Post-doc position at the biochemistry department working on **structure/activity relationship of syncytiotrophoblast molecules**.

EUROPEPTIDES
Division of Asta Medica

Vice-President, R&D, leading preclinical and clinical development of several peptide analogues (growth hormones and GnRH agonists/antagonists). During these years, I filed **two patents** and advanced **two injectable sustained release formulations** to clinical phases II and III.

aptys pharma

Founder and CEO, specializing in the design and development of **innovative formulations**. Over the course of 22 years, he collaborated with numerous start-up biotech, pharmaceutical companies, to support the progression of lead molecules into patient-ready products. His work encompassed **development strategy, formulation selection, and the design of optimal compositions for both preclinical and clinical studies**. Additionally, he developed **proprietary products**, with the goal of licensing these innovations to strategic partners.

EXAMPLES OF PRODUCTS DEVELOPED

Injectable peptide microspheres





Injectable peptide implants





Transdermal emulsions



Bioadhesive buccal tablets



Ocular tablets

Boutignon & Partners

PUBLICATIONS COMMUNICATIONS AND PATENTS

58 publications and communications and 12 patents.

Recent Conferences:

- "PLGA-Based Depot Systems with Peptides", Innovative Dosage Forms, March 2013, Essen
- "Injectable Depot Formulations of Peptides: Strategy of Development", BIT's Annual International Symposium of Drug Delivery Systems, July 2018, Saint Petersburg
- Chairman, 3rd Losan Drug Delivery Conference on Formulation Development and Technologies, February 2020, Frankfurt
- "Using nano milling to improve dissolution rate of abiraterone acetate", 4th Losan Drug Delivery Conference, February 2022, Binzen
- "Critical Steps from Peptide Discovery to Peptide Product", 23rd GFPP Meeting, September 2023, Fournol
- Chairman, 5th Losan Drug Delivery Conference, February 2024, Frankfurt

OFFER

I can help you in the several steps of early development of your molecule:

- To define the formulation needed for regulatory as well as non regulatory pre-clinical studies;
- To select the CRO accordingly;
- To supervise the operation from the request for proposal to the delivery of the report;
- To define the target product profile and quality target product profile;
- To choose the right formulation and select the CDMO accordingly;
- To supervise the operation from the request for proposal to the delivery of the product.

And in addition, if the active substance is a peptide,

- To design and improve the structure;
- To select the supplier;
- To manage the chemical development strategy according to the pre-clinical and clinical development journey of the peptide.

THANK YOU

- fb@francoisboutignon.com
- +33 6 14 15 55 52

Boutignon & Partners